Stock Ratings / Health Care / IRD / options

BNTC (37) VOGX (56) FULC (40) ENTA (25) ⌘ Pro Terminal →

Opus Genetics Inc. (IRD) Options Positioning, Max Pain & Unusual Sweeps

$3.65 -0.81% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.64

Opus Genetics Inc. (IRD) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $303.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.64 (-0.34%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IRD)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (32/100 Composite)

🔍 WHY IRD SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (38% of score)

FRED Regime × Technicals: 36% of 52W Range • RSI-14 at 39.7 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+8/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$4.65-17.4% Next Q

Q2 (-2Q)

Grade E$3.84-9.6% Next Q

Q3 (-1Q)

Grade E$3.47+5.2% Next Q

Current

Grade E$3.65-9.2% Hist 90D α

Trajectory: D (40) → E (32)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IRD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IRD currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.47) and Max Pain ($3.83) forces dealer call-delta covering toward $7.42.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IRD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IRD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 32%NO 68%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (IRD)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for IRD.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IRD)

✓Walkthrough of IRD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IRD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.57%📐 HORIZONTAL RANGE

2026-10-30O $3.58H $3.69L $3.42C $3.65VOL 1.02M

RES: $7.78SUP: $3.20SMA50: $4.47SMA200: $4.18

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IRD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IRD Butterfly Map → + Track IRD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +29.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IRD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IRD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IRD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IRD)

Health Care Rank #891 of 1016 ⚔️ BNTC vs IRD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IRD vs. BNTC, VOGX, FULC, ENTA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Opus Genetics Inc. (IRD) ranks #891 by composite RQD confidence (32/100, grade E) and #517 by equity capitalization ($303.7M). Within this direct 5-issuer industry benchmark cohort, IRD leads on earnings valuation at N/A trailing P/E, while IRD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VOGX currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with IRD at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IRD ACTIVE Opus Genetics Inc.	E	32/100	—	—	-35.0%	-0.81%	$303.7M	Benchmark Subject
BNTC Benitec Biopharma Inc.	D-	37/100	—	—	-35.0%	+0.34%	$308.1M	/bntc-vs-ird →
VOGX Vogenx Inc	D+	56/100	—	—	—	+5.29%	$295.9M	/vogx-vs-ird →
FULC Fulcrum Therapeutics Inc.	D-	40/100	—	—	-35.0%	+0.53%	$288.0M	/fulc-vs-ird →
ENTA Enanta Pharmaceuticals Inc.	E	25/100	—	—	-35.0%	-3.46%	$324.7M	/enta-vs-ird →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001228627

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Opus Genetics Inc. (IRD) reported GAAP revenue of $14.2M (+29.1% vs. FY2024 revenue of $11.0M , and -25.5% cumulative change since FY2023) , GAAP net income of -$49.6M, operating cash flow of -$35.3M, and free cash flow of -$35.3M (-37.8% YoY). On the balance sheet, IRD closed FY2025 with $50.2M in total assets against $1.1M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$14.2M	-$49.6M	-$35.3M	-$35.3M	$50.2M	$1.1M
FY2024 (FY)	2024-12-31	$11.0M	-$57.5M	-$25.6M	-$25.6M	$36.9M	$0
FY2023 (FY)	2023-12-31	$19.0M	-$10.0M	-$1.1M	-$1.1M	—	—

3. IRD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IRD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Opus Genetics Inc. (NASDAQ: IRD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.65 (-0.81% 1D, market cap $303.7M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IRD ranks #891 in composite RQD confidence.

How does IRD compare to BNTC and VOGX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IRD carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BNTC (Benitec Biopharma Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $308.1M) and VOGX (Vogenx Inc) posts a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $295.9M). Among the 5-stock peer group, IRD leads on earnings multiple (N/A) while IRD leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IRD?

Per IRD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001228627), Opus Genetics Inc. generated $14.2M in revenue (+29.1% YoY), -$49.6M in net income, and -$35.3M in free cash flow against $50.2M in total assets and $1.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IRD trading relative to its 50-day, 200-day, and 52-week technical levels?

IRD last traded at $3.65 (-0.81% on volume of 709,609 shares), positioning the stock -18.34% below its 50-day simple moving average ($4.47) and -12.68% below its 200-day simple moving average ($4.18). Across its 52-week range of $1.70 to $7.07, IRD sits at the 36.3% percentile with a 14-day RSI of 39.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.19 to $4.11).

IRD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is IRD's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for IRD.

Direct Sub-Reports: IRD RQD Cockpit IRD 12M Forecast IRD Earnings & Move IRD Dividends & DRIP IRD Insiders & 13F IRD Whale Options IRD Profit Sankey IRD News & Why